Showcases Stock ranks Forex

Apellis Pharmaceuticals Inc (APLS)
31.37  -0.63 (-1.97%) 10-22 16:00
Open: 31.94 Pre. Close: 32
High: 31.94 Low: 30.78
Volume: 777,131 Market Cap: 2,525M
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 32.149 - 32.457 32.457 - 32.644
Low: 30.13 - 30.53 30.53 - 30.772
Close: 30.908 - 31.564 31.564 - 31.961
Stock Technical Analysis
Target: Six months: 39.86
One year: 42.28
Support: Support1: 30.78
Support2: 25.61
Resistance: Resistance1: 34.13
Resistance2: 36.20
Pivot: 33.23
Moving Averages: MA(5): 32.43
MA(20): 33.45
MA(100): 53.52
MA(250): 49.42
MACD: MACD(12,26): -2.68
Signal(12,26,9): -3.30
%K %D: %K(14,3): 6.33
%D(3): 13.31
RSI: RSI(14): 31.60
52-Week: High: 73
Low: 27.5
Change(%): -12.5
Average Vol(K): 3-Month: 166465
10-Days: 80378
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.

APLS has closed above bottom band by 3.0%. Bollinger Bands are 72.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to APLS's normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Fri, 22 Oct 2021
Zacks: Analysts Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Will Post Earnings of -$1.73 Per Share - MarketBeat

Thu, 21 Oct 2021
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised) - Entrepreneur

Tue, 19 Oct 2021
Apellis (APLS) falls 1.16% to Close at $33.18 on October 19 -

Mon, 18 Oct 2021
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down on Insider Selling - MarketBeat

Mon, 18 Oct 2021
Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds? - Yahoo Finance

Sat, 16 Oct 2021
Federico Grossi Sells 750 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 80.50
Shares Float (M) 71.21
% Held by Insiders 18.86
% Held by Institutions 76.67
Shares Short (K) 5050
Shares Short Prior Month (K) 6230
Stock Financials
EPS -4.700
Book Value (p.s.) 0.640
Profit Margin -183.18
Operating Margin -126.68
Return on Assets (ttm) -25.3
Return on Equity (ttm) -1016.4
Qtrly Rev. Growth
Gross Profit (p.s.) -0.923
Sales Per Share 3.121
EBITDA (p.s.) -3.940
Qtrly Earnings Growth
Operating Cash Flow (M) -239.85
Levered Free Cash Flow (M) -87.08
Stock Valuation
PE Ratio -6.67
PEG Ratio
Price to Book value 49.02
Price to Sales 10.05
Price to Cash Flow -10.53
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator